350
Participants
Start Date
June 30, 2011
Primary Completion Date
January 31, 2013
Study Completion Date
October 31, 2013
PSI-7977
Tablets, oral, 400 mg, once daily
Daclatasvir
Tablets, oral, 60 mg, once daily
Ribavirin
Tablets, oral, 200 mg
Weill Cornell Medical College, New York
Bronx Va Medical Center 3c Sub-J, The Bronx
University Of Pennsylvania, Philadelphia
Johns Hopkins University, Lutherville
Mercy Medical Center, Baltimore
Metropolitan Research, Annandale
University Of Florida Hepatology, Gainesville
Orlando Immunology Center, Orlando
Miami Research Associates, South Miami
University Of Michigan Health System, Ann Arbor
Dean Clinic, Madison
Options Health Research, Llc, Tulsa
Healthcare Research Consultants, Tulsa
Alamo Medical Research, San Antonio
University Of Colorado Denver & Hospital, Aurora
Research And Education, Inc., San Diego
Southern California Liver Centers, Coronado
Local Institution, San Juan
Lead Sponsor
Collaborators (1)
Pharmasset
INDUSTRY
Bristol-Myers Squibb
INDUSTRY